Class Action Investigation of Rocket Pharmaceuticals
In recent developments, Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is facing scrutiny as a class action lawsuit has been initiated concerning potential violations of federal securities laws. The law firm Berger Montague PC, committed to investor protection, has stepped forward to investigate claims that allegations surfaced regarding concealed safety issues in relation to the company’s RP-A501 clinical trial.
About Rocket Pharmaceuticals
Headquartered in New Jersey, Rocket Pharmaceuticals is at the forefront of innovative research and clinical programs in genetic medicine. The company focuses on developing transformative therapies aimed at life-threatening genetic diseases.
Allegations of Concealment
The crux of the lawsuit revolves around the introduction of a novel immunomodulatory agent into the RP-A501 trial. Allegations assert that this crucial information was not communicated to shareholders prior to a tragic incident involving a patient, resulting in a fatal adverse event. Following this, an FDA clinical hold was announced, leading to a staggering 37% decline in stock price within just two trading days.
Eligibility to Join the Class Action
Individuals who invested in Rocket Pharmaceuticals securities between February 27, 2025, and May 26, 2025, may qualify to join this class action. The critical deadline for filing as a lead plaintiff is set for August 11, 2025. It is essential for investors to explore their rights and consider their options during this investigation.
Legal Support and Resources
Berger Montague, established in 1970, has long operated as a stalwart in securities class action litigation. With offices across several major U.S. cities, this firm has successfully represented both individual and institutional investors over the past five decades. Their extensive experience makes them uniquely positioned to guide affected investors through this tumultuous period.
How to Reach Out
Individuals seeking more clarity on their rights or any further information can connect with:
Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
aabramowitz@bergermontague.com
Caitlin Adorni
Berger Montague
(267) 764-4865
cadorni@bergermontague.com
Frequently Asked Questions
What is the reason behind the class action against Rocket Pharmaceuticals?
The class action is initiated due to allegations that Rocket Pharmaceuticals concealed safety data regarding its RP-A501 trial, which may have negatively impacted investors.
Who is eligible to participate in the class action?
Investors who purchased Rocket Pharmaceuticals stocks between February 27, 2025, and May 26, 2025, can join the class action.
What is the deadline for filing as a lead plaintiff?
The deadline for filing as a lead plaintiff in the lawsuit is August 11, 2025.
How can I contact the firm handling the case?
You can reach Berger Montague at their Philadelphia office, or contact Andrew Abramowitz or Caitlin Adorni directly via phone or email.
What are the potential outcomes of the class action?
Depending on the investigation’s outcome, affected investors may receive compensation for their losses if the court rules in favor of the plaintiffs.
